Vicente, Phebe A.
HRN: 00-97-92 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/18/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
04/18/2025
04/25/2025
IV
4.5gm LD Then 2.25gm Q8h
Q8h
CAP MR, SEPSIS
Waiting Final Action
Indication: Empiric Type of Infection: PneumoniaBloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes